Nkarta Inc

Research Nkarta Inc (NKTX) on Bullrun: market cap USD 203.90M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNKTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 203.90M
• Financial periodFY2025
• Net income-USD 104.08M
• Free cash flow-USD 89.91M

Valuation Snapshot

latest market cap is USD 203.90M.

About Nkarta Inc

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy;

Frequently asked questions

What is Nkarta Inc's market cap?

Nkarta Inc's market capitalization is USD 203.90M.

What does Nkarta Inc do?

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.